Search

Your search keyword '"Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy"' showing total 8,626 results

Search Constraints

Start Over You searched for: Descriptor "Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy" Remove constraint Descriptor: "Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy"
8,626 results on '"Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy"'

Search Results

1. Enhanced induction of apoptosis in chronic myeloid leukemia cells through synergistic effect of telomerase inhibitor MST-312 and imatinib.

2. Development of an hollow fiber solid phase microextraction method for the analysis of unbound fraction of imatinib and N-desmethyl imatinib in human plasma.

3. Oxidative lipid damage by naringenin selectively sensitizes chronic myeloid leukemia cell lines and patient samples to Bcr-Abl tyrosine kinase inhibitors.

4. Single-cell multiomics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response.

5. Predicting drug resistance.

6. [Analysis of treatment-free remission outcomes in patients with chronic myeloid leukemia who received sequential nilotinib therapy after achieving deep molecular response to imatinib].

7. A Novel Next-Generation Sequencing Assay for the Identification of BCR::ABL1 Transcript Type and Accurate and Sensitive Detection of TKI-Resistant Mutations.

8. Vitamin K2 Protects Against SARS-CoV-2 Envelope Protein-Induced Cytotoxicity in Chronic Myeloid Leukemia Cells and Enhances Imatinib Activity.

9. Health-Related Quality of Life and Financial Burden in Ethiopian Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Study.

10. Clinical Pharmacology of Asciminib: A Review.

12. Structure optimization, synthesis and bioactivity evaluation of novel BCR-ABL tyrosine kinase inhibitor targeting T315I mutation.

13. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial.

14. Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy.

15. Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib.

16. Celastrol induces DNA damage and cell death in BCR-ABL T315I-mutant CML by targeting YY1 and HMCES.

17. Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients.

18. Varying concentrations of tyrosine kinase inhibitors in chronic myeloid leukemia patients following bariatric surgery: a case series.

19. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring.

20. A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia.

21. Clinicopathologic features of pityriasis rosea-like drug eruption secondary to imatinib: A case report and review of the literature.

22. Tyrosine Kinase Inhibitor-induced Cerebrovascular Occlusion Presenting with Moyamoya Disease-like Stenosis of the Circle of Willis.

23. Bilateral forearm compartment syndrome in a patient with recently diagnosed chronic myeloid leukaemia.

24. A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.

25. Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells.

26. Tyrosine kinase inhibitor for CML: all the same?

27. Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study.

28. Targeting Oxidative Phosphorylation with a Novel Thiophene Carboxamide Increases the Efficacy of Imatinib against Leukemic Stem Cells in Chronic Myeloid Leukemia.

29. Computationally Driven Discovery of a BCR-ABL1 Kinase Inhibitor with Activity in Multidrug-Resistant Chronic Myeloid Leukemia.

30. Compound K Promotes Megakaryocytic Differentiation by NLRP3 Inflammasome Activation.

31. Synchronous presentation of recurrent intracranial solitary fibrous tumour and chronic myeloid leukaemia: a diagnostic challenge.

32. [Halving Time of BCR-ABL Transcripts as a Precise Predictor for Deep Molecular Response in Patients with Chronic Myeloid Leukemia Treated with TKI].

33. Determination of Serum Myeloperoxidase (MPO) and lactate dehydrogenase (LDH) as a tumour Marker in Chronic Myeloid Leukaemia (CML).

34. Phenotypically plastic drug-resistant chronic myeloid leukaemia cell line displays enhanced cellular dynamics in a zebrafish xenograft model.

35. Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.

36. FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation.

37. Is there really an accelerated phase of chronic myeloid leukaemia?

38. Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events.

39. Palpebral toxicity of Nilotinib Capsules: a rare chalazion.

40. Clinical Characteristics and Outcomes of CML in Adolescents and Young Adults.

41. Achievement of deep molecular response and treatment-free remission with asciminib treatment in CML.

42. A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial).

43. Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial.

44. Peripheral blood quantitation of CD26 positive leukemic stem cells as a predictor of tyrosine kinase inhibitor response in chronic myeloid leukemia.

45. Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study.

46. Pediatric secondary chronic myelogenous leukemia in a patient with hemophagocytic lymphohistiocytosis carrying UNC13D, LYST, and ITK variants.

47. Oral lesions associated with imatinib mesylate therapy: five new cases and a literature review.

48. Natural compounds combined with imatinib as promising antileukemic therapy: An updated review.

49. Effects of imidazole derivatives on cellular proliferation and apoptosis in myeloid leukemia.

50. PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation.

Catalog

Books, media, physical & digital resources